Sam Brusco, Associate Editor04.21.23
Olympus has launched its EndoClot adhesive (ECA), EndoClot polysaccharide hemostatic spray (PHS), and EndoClot submucosal injection solution (SIS) in the Europe, Middle East and Africa (EMEA) region.
The portfolio is developed by EndoClot Plus (EPI), which grew its distribution deal with Olympus from the U.S. to EMEA in December 2022.
"We are excited to expand our global partnership with EndoClot Plus, Inc. The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures," Stefanie Kaufung, EMEA Business Unit Manager GI EndoTherapy at Olympus, told the press. "Endoscopic resection and associated bleeding management are among Olympus' core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care."
EndoClot ECA is a single-use device to seal lesions. It consists of hemostatic polymer (AHP), which is resistant to acids and bases in the GI tract. It’s recommended to only be used at the end of the procedure to stop and control oozing bleeding, prevent re-bleeding, and protect the wound from irritation.
EndoClot PHS and SIS are based on EndoClot absorbable, starch-derived modified polymer (AMP) tech. AMP particles absorb water from the blood and the dehydration process causes a high concentration of platelets, red blood cells, and coagulation proteins to accelerate clotting.
"EndoClot SIS supports me to have a long-lasting mucosal lift with high elevation to create effective mucosal separation and enabling precise ESD/EMR; whereas EndoClot PHS and ECA can provide expanded options to address emergent and residual bleeding or prevent re-bleeding at resection sites," said Dr. David Tate, Medical Doctor at University Hospital of Gent, Belgium.
The portfolio is developed by EndoClot Plus (EPI), which grew its distribution deal with Olympus from the U.S. to EMEA in December 2022.
"We are excited to expand our global partnership with EndoClot Plus, Inc. The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures," Stefanie Kaufung, EMEA Business Unit Manager GI EndoTherapy at Olympus, told the press. "Endoscopic resection and associated bleeding management are among Olympus' core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care."
EndoClot ECA is a single-use device to seal lesions. It consists of hemostatic polymer (AHP), which is resistant to acids and bases in the GI tract. It’s recommended to only be used at the end of the procedure to stop and control oozing bleeding, prevent re-bleeding, and protect the wound from irritation.
EndoClot PHS and SIS are based on EndoClot absorbable, starch-derived modified polymer (AMP) tech. AMP particles absorb water from the blood and the dehydration process causes a high concentration of platelets, red blood cells, and coagulation proteins to accelerate clotting.
"EndoClot SIS supports me to have a long-lasting mucosal lift with high elevation to create effective mucosal separation and enabling precise ESD/EMR; whereas EndoClot PHS and ECA can provide expanded options to address emergent and residual bleeding or prevent re-bleeding at resection sites," said Dr. David Tate, Medical Doctor at University Hospital of Gent, Belgium.